Lilly is struggling to find the talent required for these capital expenditure projects, says Steve Marr, head of the drugmaker’s global facilities delivery parenteral.
The new facility at Flatiron Park in Boulder will support process development and analytical services adjacent to the company’s peptide API manufacturing site.
